Evaluation and treatment of vasculitis in the critically ill patient

Critical Care Clinics

Volumn 18, Issue 2, 2002, Pages 321-344

  Merkel, Peter A ^a   Choi, Hyon K ^b   Niles, John L ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY; BIOLOGICAL MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

BLADDER DISEASE; BRONCHOSCOPY; CLINICAL FEATURE; CLINICAL TRIAL; CRITICAL ILLNESS; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; EARLY DIAGNOSIS; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; LUNG BIOPSY; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SERODIAGNOSIS; VASCULITIS; ARTERITIS; BRAIN VASCULITIS; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; IMMUNOLOGY; INTENSIVE CARE UNIT; METABOLISM;

ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ARTERITIS; BIOLOGICAL MARKERS; CRYOGLOBULINEMIA; HUMANS; INTENSIVE CARE UNITS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; VASCULITIS;

EID: 0036014089     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(01)00006-9     Document Type: Article

References (91)

1. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
2. Mixed cryoglobulinemia secondary to hepatitis C virus infection
3. Gadolinium contrast magnetic resonance imaging of the temporal artery in giant cell arteritis
4. The catastrophic antiphospholipid syndrome
5. Catastrophic antiphospho-lipid syndrome. Clinical and laboratory features of 50 patients
6. Treatment of lupus nephritis
7. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods
8. Disease pattern in cranial and large-vessel giant cell arteritis
9. Lupus nephritis: An historical perspective 1968-1998
10. Cardiopulmonary manifestations of systemic lupus erythematous
11. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
12. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: Metaanalysis with a focus on antimyelo-peroxidase antibodies
13. Drug-associated ANCA-positive vasculitis: Prevalence among patients with high titers of anti-myeloperoxidase antibodies
14. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis
15. Antimyeloperoxidase antibodies in the Churg-Strauss syndrome
16. Anti-myeloperoxidase antibodies in Churg-Strauss syndrome
17. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis
18. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole
19. Hepatitis C
20. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane
21. Alveolar hemorrhage in patients with rheumatic disease
22. Pulmonary hemorrhage in systemic lupus erythematosus
23. Polymyalgia rheumatica and giant cell arteritis
24. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloper-oxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
25. ANCA small-vessel vasculitis
26. The spectrum of vasculitis: Clinical, pathologic, immunologic and therapeutic considerations
27. Neuropsychiatric manifestations of systemic lupus erythematosus: Diagnosis, clinical spectrum, and relationship to other features of the disease
28. Correlation of anti-neutrophil cytoplasmic antibodies with the extra-renal histopathology of Wegener's (pathergic) granulomatosis and related forms of vasculitis
29. The clinical application of "edema-weighted" magnetic resonance imaging in the assessment of Takayasu's arteritis
30. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients
31. Pulmonary capillaritis and alveolar hemorrhage: Update on diagnosis and management
32. Antineutrophil cytoplasmic autoantibody testing in vasculitis
33. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients
34. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization
35. Giant cell arteritis associated with rheumatoid arthritis monitored by magnetic resonance angiography
36. The antiphospholipid syndrome. Diagnosis, management, and pathogenesis
37. Comparison of anti-GBM antibodies in sera with or without ANCA
38. A multicenter placebo-controlled study of methotrexate (MTX) in giant cell artertitis (GCA)
39. Wegener granulomatosis: An analysis of 158 patients
40. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
41. Treatment of gluco-corticoid-resistant or relapsing Takayasu arteritis with methotrexate
42. Goodpasture syndrome: Molecular architecture and function of basement membrane antigen
43. Update on the European Vasculitis Study Group trials
44. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
45. ANCA predicting relapse in systemic vasculitis
46. Nomenclature of systemic vasculitis, proposal of an international conference
47. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis
48. Multifocal dural enhancement associated with temporal arteritis
49. The neurological manifestations of systemic lupus erythematosus
50. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial
51. Takayasu arteritis
52. Cryoglobulinemic vasculitis
53. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis
54. Methotrexate use in systemic vasculitis
55. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis
56. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression
57. Illustrated histopathologic classification criteria for selected vasculitis syndromes
58. Aortic and extracranial large vessel giant cell arteritis: A review of 72 cases with histopathologic documentation
59. Antiphospholipid antibody syndrome
60. New treatment strategies for systemic vasculitis: The role of intravenous immune globulin therapy
61. EVS: A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZEREM)
62. Pulmonary renal syndromes - A review
63. Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis
64. Drug-induced vasculitis
65. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease
66. Acute massive pulmonary hemorrhage in systemic lupus erythematosus
67. Giant cell arteritis and magnetic resonance angiography
68. Antineutrophil cytoplasmic autoantibodies in the classification of vasculitis
69. A renal biopsy is essential for the management of ANCA-positive patients with glomerulonephritis: The contra-view
70. Value of antigen-specific radioimmunoassays for measuring anti-neutrophil cytoplasmic antibodies (ANCA) in the differential diagnosis of rapidly progressive glomerulonephritis
71. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis
72. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement
73. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level
74. Gadolinium-enhanced MR aortography
75. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies
76. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases
77. Primary systemic vasculitis
78. A rapid assay for circulating anti-glomerular basement membrane antibodies in Goodpasture syndrome
79. Vasculitis in the seriously ill patient: Diagnostic approaches and therapeutic options in ANCA-associated vasculitis
80. Efficacy of transbronchial biopsy in pulmonary vaculitides
81. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone
82. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice
83. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
84. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients
85. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)
86. Transverse myelitis and acute central nervous system manifestations of systemic lupus erythematosus
87. Goodpasture antigen of the glomerular basement membrane: Localization to noncollagenous regions of type IV collagen
88. Takayasu arteritis: Diagnosis with breath-hold contrast-enhanced three-dimensional MR angiography
89. Colonic perforations in systemic lupus erythematosus